Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 12569 entries
Sorted by: Best Match Show Resources per page
Gastrodin Inhibits Store-Operated Ca.

Frontiers in pharmacology

Zheng C, Lo CY, Meng Z, Li Z, Zhong M, Zhang P, Lu J, Yang Z, Yan F, Zhang Y, Huang Y, Yao X.
PMID: 28487655
Front Pharmacol. 2017 Apr 25;8:222. doi: 10.3389/fphar.2017.00222. eCollection 2017.

Cardiac hypertrophy is a major risk factor for heart failure, which are among the leading causes of human death. Gastrodin is a small molecule that has been used clinically to treat neurological and vascular diseases for many years without...

Cite
Zheng C, Lo CY, Meng Z, et al. Gastrodin Inhibits Store-Operated Ca. Front Pharmacol. 2017;8:222doi: 10.3389/fphar.2017.00222.
Zheng, C., Lo, C. Y., Meng, Z., Li, Z., Zhong, M., Zhang, P., Lu, J., Yang, Z., Yan, F., Zhang, Y., Huang, Y., & Yao, X. (2017). Gastrodin Inhibits Store-Operated Ca. Frontiers in pharmacology, 8222. https://doi.org/10.3389/fphar.2017.00222
Zheng, Changbo, et al. "Gastrodin Inhibits Store-Operated Ca." Frontiers in pharmacology vol. 8 (2017): 222. doi: https://doi.org/10.3389/fphar.2017.00222
Zheng C, Lo CY, Meng Z, Li Z, Zhong M, Zhang P, Lu J, Yang Z, Yan F, Zhang Y, Huang Y, Yao X. Gastrodin Inhibits Store-Operated Ca. Front Pharmacol. 2017 Apr 25;8:222. doi: 10.3389/fphar.2017.00222. eCollection 2017. PMID: 28487655; PMCID: PMC5404510.
Copy Download .nbib Format: NLM
Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy.

Frontiers in pharmacology

Peres FF, Levin R, Almeida V, Zuardi AW, Hallak JE, Crippa JA, Abilio VC.
PMID: 27667973
Front Pharmacol. 2016 Sep 09;7:303. doi: 10.3389/fphar.2016.00303. eCollection 2016.

Schizophrenia is a severe psychiatric disorder that involves positive, negative and cognitive symptoms. Prepulse inhibition of startle reflex (PPI) is a paradigm that assesses the sensorimotor gating functioning and is impaired in schizophrenia patients as well as in animal...

Cite
Peres FF, Levin R, Almeida V, et al. Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy. Front Pharmacol. 2016;7:303doi: 10.3389/fphar.2016.00303.
Peres, F. F., Levin, R., Almeida, V., Zuardi, A. W., Hallak, J. E., Crippa, J. A., & Abilio, V. C. (2016). Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy. Frontiers in pharmacology, 7303. https://doi.org/10.3389/fphar.2016.00303
Peres, Fernanda F, et al. "Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy." Frontiers in pharmacology vol. 7 (2016): 303. doi: https://doi.org/10.3389/fphar.2016.00303
Peres FF, Levin R, Almeida V, Zuardi AW, Hallak JE, Crippa JA, Abilio VC. Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy. Front Pharmacol. 2016 Sep 09;7:303. doi: 10.3389/fphar.2016.00303. eCollection 2016. PMID: 27667973; PMCID: PMC5016523.
Copy Download .nbib Format: NLM
[No title available]

Frontiers in pharmacology

Su HH, Chu YC, Liao JM, Wang YH, Jan MS, Lin CW, Wu CY, Tseng CY, Yen JC, Huang SS.
PMID: 28420993
Front Pharmacol. 2017 Apr 04;8:175. doi: 10.3389/fphar.2017.00175. eCollection 2017.

The incidence of myocardial ischemia-reperfusion (IR) injury is rapidly increasing around the world and this disease is a major contributor to global morbidity and mortality. It is known that regulation of programmed cell death including apoptosis and autophagy reduces...

Cite
Su HH, Chu YC, Liao JM, et al. . Front Pharmacol. 2017;8:175doi: 10.3389/fphar.2017.00175.
Su, H. H., Chu, Y. C., Liao, J. M., Wang, Y. H., Jan, M. S., Lin, C. W., Wu, C. Y., Tseng, C. Y., Yen, J. C., & Huang, S. S. (2017). . Frontiers in pharmacology, 8175. https://doi.org/10.3389/fphar.2017.00175
Su, Hsing-Hui, et al. "." Frontiers in pharmacology vol. 8 (2017): 175. doi: https://doi.org/10.3389/fphar.2017.00175
Su HH, Chu YC, Liao JM, Wang YH, Jan MS, Lin CW, Wu CY, Tseng CY, Yen JC, Huang SS. . Front Pharmacol. 2017 Apr 04;8:175. doi: 10.3389/fphar.2017.00175. eCollection 2017. PMID: 28420993; PMCID: PMC5378821.
Copy Download .nbib Format: NLM
MSCs-Derived Exosomes: Cell-Secreted Nanovesicles with Regenerative Potential.

Frontiers in pharmacology

Marote A, Teixeira FG, Mendes-Pinheiro B, Salgado AJ.
PMID: 27536241
Front Pharmacol. 2016 Aug 03;7:231. doi: 10.3389/fphar.2016.00231. eCollection 2016.

Exosomes are membrane-enclosed nanovesicles (30-150 nm) that shuttle active cargoes between different cells. These tiny extracellular vesicles have been recently isolated from mesenchymal stem cells (MSCs) conditioned medium, a population of multipotent cells identified in several adult tissues. MSCs...

Cite
Marote A, Teixeira FG, Mendes-Pinheiro B, et al. MSCs-Derived Exosomes: Cell-Secreted Nanovesicles with Regenerative Potential. Front Pharmacol. 2016;7:231doi: 10.3389/fphar.2016.00231.
Marote, A., Teixeira, F. G., Mendes-Pinheiro, B., & Salgado, A. J. (2016). MSCs-Derived Exosomes: Cell-Secreted Nanovesicles with Regenerative Potential. Frontiers in pharmacology, 7231. https://doi.org/10.3389/fphar.2016.00231
Marote, Ana, et al. "MSCs-Derived Exosomes: Cell-Secreted Nanovesicles with Regenerative Potential." Frontiers in pharmacology vol. 7 (2016): 231. doi: https://doi.org/10.3389/fphar.2016.00231
Marote A, Teixeira FG, Mendes-Pinheiro B, Salgado AJ. MSCs-Derived Exosomes: Cell-Secreted Nanovesicles with Regenerative Potential. Front Pharmacol. 2016 Aug 03;7:231. doi: 10.3389/fphar.2016.00231. eCollection 2016. PMID: 27536241; PMCID: PMC4971062.
Copy Download .nbib Format: NLM
Azilsartan as a Potent Antihypertensive Drug with Possible Pleiotropic Cardiometabolic Effects: A Review Study.

Frontiers in pharmacology

Georgiopoulos G, Katsi V, Oikonomou D, Vamvakou G, Koutli E, Laina A, Tsioufis C, Nihoyannopoulos P, Tousoulis D.
PMID: 27536242
Front Pharmacol. 2016 Aug 03;7:235. doi: 10.3389/fphar.2016.00235. eCollection 2016.

BACKGROUND: Hypertension related cardiovascular (CV) complications could be amplified by the presence of metabolic co-morbidities. Azilsartan medoxomil (AZL-M) is the eighth approved member of angiotensin II receptor blockers (ARBs), a drug class of high priority in the management of...

Cite
Georgiopoulos G, Katsi V, Oikonomou D, et al. Azilsartan as a Potent Antihypertensive Drug with Possible Pleiotropic Cardiometabolic Effects: A Review Study. Front Pharmacol. 2016;7:235doi: 10.3389/fphar.2016.00235.
Georgiopoulos, G., Katsi, V., Oikonomou, D., Vamvakou, G., Koutli, E., Laina, A., Tsioufis, C., Nihoyannopoulos, P., & Tousoulis, D. (2016). Azilsartan as a Potent Antihypertensive Drug with Possible Pleiotropic Cardiometabolic Effects: A Review Study. Frontiers in pharmacology, 7235. https://doi.org/10.3389/fphar.2016.00235
Georgiopoulos, Georgios, et al. "Azilsartan as a Potent Antihypertensive Drug with Possible Pleiotropic Cardiometabolic Effects: A Review Study." Frontiers in pharmacology vol. 7 (2016): 235. doi: https://doi.org/10.3389/fphar.2016.00235
Georgiopoulos G, Katsi V, Oikonomou D, Vamvakou G, Koutli E, Laina A, Tsioufis C, Nihoyannopoulos P, Tousoulis D. Azilsartan as a Potent Antihypertensive Drug with Possible Pleiotropic Cardiometabolic Effects: A Review Study. Front Pharmacol. 2016 Aug 03;7:235. doi: 10.3389/fphar.2016.00235. eCollection 2016. PMID: 27536242; PMCID: PMC4971108.
Copy Download .nbib Format: NLM
Preparation and Distribution of Cannabis and Cannabis-Derived Dosage Formulations for Investigational and Therapeutic Use in the United States.

Frontiers in pharmacology

Thomas BF, Pollard GT.
PMID: 27630566
Front Pharmacol. 2016 Aug 31;7:285. doi: 10.3389/fphar.2016.00285. eCollection 2016.

Cannabis is classified as a schedule I controlled substance by the US Drug Enforcement Agency, meaning that it has no medicinal value. Production is legally restricted to a single supplier at the University of Mississippi, and distribution to researchers...

Cite
Thomas BF, Pollard GT. Preparation and Distribution of Cannabis and Cannabis-Derived Dosage Formulations for Investigational and Therapeutic Use in the United States. Front Pharmacol. 2016;7:285doi: 10.3389/fphar.2016.00285.
Thomas, B. F., & Pollard, G. T. (2016). Preparation and Distribution of Cannabis and Cannabis-Derived Dosage Formulations for Investigational and Therapeutic Use in the United States. Frontiers in pharmacology, 7285. https://doi.org/10.3389/fphar.2016.00285
Thomas, Brian F, and Pollard, Gerald T. "Preparation and Distribution of Cannabis and Cannabis-Derived Dosage Formulations for Investigational and Therapeutic Use in the United States." Frontiers in pharmacology vol. 7 (2016): 285. doi: https://doi.org/10.3389/fphar.2016.00285
Thomas BF, Pollard GT. Preparation and Distribution of Cannabis and Cannabis-Derived Dosage Formulations for Investigational and Therapeutic Use in the United States. Front Pharmacol. 2016 Aug 31;7:285. doi: 10.3389/fphar.2016.00285. eCollection 2016. PMID: 27630566; PMCID: PMC5006560.
Copy Download .nbib Format: NLM
Cost-Effectiveness of Pediatric Central Venous Catheters in the UK: A Secondary Publication from the CATCH Clinical Trial.

Frontiers in pharmacology

Ridyard CH, Plumpton CO, Gilbert RE, Hughes DA.
PMID: 28974929
Front Pharmacol. 2017 Sep 19;8:644. doi: 10.3389/fphar.2017.00644. eCollection 2017.

No abstract available.

Cite
Ridyard CH, Plumpton CO, Gilbert RE, et al. Cost-Effectiveness of Pediatric Central Venous Catheters in the UK: A Secondary Publication from the CATCH Clinical Trial. Front Pharmacol. 2017;8:644doi: 10.3389/fphar.2017.00644.
Ridyard, C. H., Plumpton, C. O., Gilbert, R. E., & Hughes, D. A. (2017). Cost-Effectiveness of Pediatric Central Venous Catheters in the UK: A Secondary Publication from the CATCH Clinical Trial. Frontiers in pharmacology, 8644. https://doi.org/10.3389/fphar.2017.00644
Ridyard, Colin H, et al. "Cost-Effectiveness of Pediatric Central Venous Catheters in the UK: A Secondary Publication from the CATCH Clinical Trial." Frontiers in pharmacology vol. 8 (2017): 644. doi: https://doi.org/10.3389/fphar.2017.00644
Ridyard CH, Plumpton CO, Gilbert RE, Hughes DA. Cost-Effectiveness of Pediatric Central Venous Catheters in the UK: A Secondary Publication from the CATCH Clinical Trial. Front Pharmacol. 2017 Sep 19;8:644. doi: 10.3389/fphar.2017.00644. eCollection 2017. PMID: 28974929; PMCID: PMC5610787.
Copy Download .nbib Format: NLM
Induction of Mkp-1 and Nuclear Translocation of Nrf2 by Limonoids from .

Frontiers in pharmacology

Kouam AF, Yuan F, Njayou FN, He H, Tsayem RF, Oladejo BO, Song F, Moundipa PF, Gao GF.
PMID: 28974930
Front Pharmacol. 2017 Sep 19;8:653. doi: 10.3389/fphar.2017.00653. eCollection 2017.

Drug-induced liver injury (DILI) is a major clinical problem where natural compounds hold promise for its abrogation.

Cite
Kouam AF, Yuan F, Njayou FN, et al. Induction of Mkp-1 and Nuclear Translocation of Nrf2 by Limonoids from . Front Pharmacol. 2017;8:653doi: 10.3389/fphar.2017.00653.
Kouam, A. F., Yuan, F., Njayou, F. N., He, H., Tsayem, R. F., Oladejo, B. O., Song, F., Moundipa, P. F., & Gao, G. F. (2017). Induction of Mkp-1 and Nuclear Translocation of Nrf2 by Limonoids from . Frontiers in pharmacology, 8653. https://doi.org/10.3389/fphar.2017.00653
Kouam, Arnaud F, et al. "Induction of Mkp-1 and Nuclear Translocation of Nrf2 by Limonoids from ." Frontiers in pharmacology vol. 8 (2017): 653. doi: https://doi.org/10.3389/fphar.2017.00653
Kouam AF, Yuan F, Njayou FN, He H, Tsayem RF, Oladejo BO, Song F, Moundipa PF, Gao GF. Induction of Mkp-1 and Nuclear Translocation of Nrf2 by Limonoids from . Front Pharmacol. 2017 Sep 19;8:653. doi: 10.3389/fphar.2017.00653. eCollection 2017. PMID: 28974930; PMCID: PMC5610691.
Copy Download .nbib Format: NLM
Ca(2+)-Currents in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Effects of Two Different Culture Conditions.

Frontiers in pharmacology

Uzun AU, Mannhardt I, Breckwoldt K, Horváth A, Johannsen SS, Hansen A, Eschenhagen T, Christ T.
PMID: 27672365
Front Pharmacol. 2016 Sep 12;7:300. doi: 10.3389/fphar.2016.00300. eCollection 2016.

Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) provide a unique opportunity to study human heart physiology and pharmacology and repair injured hearts. The suitability of hiPSC-CM critically depends on how closely they share physiological properties of human adult cardiomyocytes...

Cite
Uzun AU, Mannhardt I, Breckwoldt K, et al. Ca(2+)-Currents in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Effects of Two Different Culture Conditions. Front Pharmacol. 2016;7:300doi: 10.3389/fphar.2016.00300.
Uzun, A. U., Mannhardt, I., Breckwoldt, K., Horváth, A., Johannsen, S. S., Hansen, A., Eschenhagen, T., & Christ, T. (2016). Ca(2+)-Currents in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Effects of Two Different Culture Conditions. Frontiers in pharmacology, 7300. https://doi.org/10.3389/fphar.2016.00300
Uzun, Ahmet U, et al. "Ca(2+)-Currents in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Effects of Two Different Culture Conditions." Frontiers in pharmacology vol. 7 (2016): 300. doi: https://doi.org/10.3389/fphar.2016.00300
Uzun AU, Mannhardt I, Breckwoldt K, Horváth A, Johannsen SS, Hansen A, Eschenhagen T, Christ T. Ca(2+)-Currents in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Effects of Two Different Culture Conditions. Front Pharmacol. 2016 Sep 12;7:300. doi: 10.3389/fphar.2016.00300. eCollection 2016. PMID: 27672365; PMCID: PMC5018497.
Copy Download .nbib Format: NLM
A Standardized Chemically Modified Curcuma longa Extract Modulates IRAK-MAPK Signaling in Inflammation and Potentiates Cytotoxicity.

Frontiers in pharmacology

Rana M, Maurya P, Reddy SS, Singh V, Ahmad H, Dwivedi AK, Dikshit M, Barthwal MK.
PMID: 27504095
Front Pharmacol. 2016 Jul 25;7:223. doi: 10.3389/fphar.2016.00223. eCollection 2016.

The TLR/IL-1R pathway is a critical signaling module that is misregulated in pathologies like inflammation and cancer. Extracts from turmeric (Curcuma longa L.) enriched in curcumin and carbonyls like turmerones have been shown to exert potent anti-inflammatory effects. The...

Cite
Rana M, Maurya P, Reddy SS, et al. A Standardized Chemically Modified Curcuma longa Extract Modulates IRAK-MAPK Signaling in Inflammation and Potentiates Cytotoxicity. Front Pharmacol. 2016;7:223doi: 10.3389/fphar.2016.00223.
Rana, M., Maurya, P., Reddy, S. S., Singh, V., Ahmad, H., Dwivedi, A. K., Dikshit, M., & Barthwal, M. K. (2016). A Standardized Chemically Modified Curcuma longa Extract Modulates IRAK-MAPK Signaling in Inflammation and Potentiates Cytotoxicity. Frontiers in pharmacology, 7223. https://doi.org/10.3389/fphar.2016.00223
Rana, Minakshi, et al. "A Standardized Chemically Modified Curcuma longa Extract Modulates IRAK-MAPK Signaling in Inflammation and Potentiates Cytotoxicity." Frontiers in pharmacology vol. 7 (2016): 223. doi: https://doi.org/10.3389/fphar.2016.00223
Rana M, Maurya P, Reddy SS, Singh V, Ahmad H, Dwivedi AK, Dikshit M, Barthwal MK. A Standardized Chemically Modified Curcuma longa Extract Modulates IRAK-MAPK Signaling in Inflammation and Potentiates Cytotoxicity. Front Pharmacol. 2016 Jul 25;7:223. doi: 10.3389/fphar.2016.00223. eCollection 2016. PMID: 27504095; PMCID: PMC4959270.
Copy Download .nbib Format: NLM
Editorial: Today's Nutrition and Tomorrow's Public Health: Challenges and Opportunities.

Frontiers in pharmacology

Lenoir-Wijnkoop I, Gutiérrez-Ibarluzea I, Dubois DJ.
PMID: 26941645
Front Pharmacol. 2016 Feb 24;7:34. doi: 10.3389/fphar.2016.00034. eCollection 2016.

No abstract available.

Cite
Lenoir-Wijnkoop I, Gutiérrez-Ibarluzea I, Dubois DJ. Editorial: Today's Nutrition and Tomorrow's Public Health: Challenges and Opportunities. Front Pharmacol. 2016;7:34doi: 10.3389/fphar.2016.00034.
Lenoir-Wijnkoop, I., Gutiérrez-Ibarluzea, I., & Dubois, D. J. (2016). Editorial: Today's Nutrition and Tomorrow's Public Health: Challenges and Opportunities. Frontiers in pharmacology, 734. https://doi.org/10.3389/fphar.2016.00034
Lenoir-Wijnkoop, Irene, et al. "Editorial: Today's Nutrition and Tomorrow's Public Health: Challenges and Opportunities." Frontiers in pharmacology vol. 7 (2016): 34. doi: https://doi.org/10.3389/fphar.2016.00034
Lenoir-Wijnkoop I, Gutiérrez-Ibarluzea I, Dubois DJ. Editorial: Today's Nutrition and Tomorrow's Public Health: Challenges and Opportunities. Front Pharmacol. 2016 Feb 24;7:34. doi: 10.3389/fphar.2016.00034. eCollection 2016. PMID: 26941645; PMCID: PMC4764730.
Copy Download .nbib Format: NLM
Pharmacological Intervention in Hepatic Stellate Cell Activation and Hepatic Fibrosis.

Frontiers in pharmacology

Schon HT, Bartneck M, Borkham-Kamphorst E, Nattermann J, Lammers T, Tacke F, Weiskirchen R.
PMID: 26941644
Front Pharmacol. 2016 Feb 24;7:33. doi: 10.3389/fphar.2016.00033. eCollection 2016.

The activation and transdifferentiation of hepatic stellate cells (HSCs) into contractile, matrix-producing myofibroblasts (MFBs) are central events in hepatic fibrogenesis. These processes are driven by autocrine- and paracrine-acting soluble factors (i.e., cytokines and chemokines). Proof-of-concept studies of the last...

Cite
Schon HT, Bartneck M, Borkham-Kamphorst E, et al. Pharmacological Intervention in Hepatic Stellate Cell Activation and Hepatic Fibrosis. Front Pharmacol. 2016;7:33doi: 10.3389/fphar.2016.00033.
Schon, H. T., Bartneck, M., Borkham-Kamphorst, E., Nattermann, J., Lammers, T., Tacke, F., & Weiskirchen, R. (2016). Pharmacological Intervention in Hepatic Stellate Cell Activation and Hepatic Fibrosis. Frontiers in pharmacology, 733. https://doi.org/10.3389/fphar.2016.00033
Schon, Hans-Theo, et al. "Pharmacological Intervention in Hepatic Stellate Cell Activation and Hepatic Fibrosis." Frontiers in pharmacology vol. 7 (2016): 33. doi: https://doi.org/10.3389/fphar.2016.00033
Schon HT, Bartneck M, Borkham-Kamphorst E, Nattermann J, Lammers T, Tacke F, Weiskirchen R. Pharmacological Intervention in Hepatic Stellate Cell Activation and Hepatic Fibrosis. Front Pharmacol. 2016 Feb 24;7:33. doi: 10.3389/fphar.2016.00033. eCollection 2016. PMID: 26941644; PMCID: PMC4764688.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 12569 entries